NVSEF News and Press, Novartis Ag Basel Akt From 09/16/22

Summary Teva Pharmaceutical's divestments have been many in recent years, and the company presents a different set-up than in the past. In about 5 years Teva Pharmaceutical has reduced its net debt by $14 billion, a remarkable sum for a company with a market cap of only $10 billio...

Summary A high level of restructuring is occurring with the Healthcare industry’s largest constituents. Most restructuring is taking the form of splits or spin-offs, but not all incidences look beneficial. This article will summarize coming transactions and provide comm...

Summary Due to its tremendous pressure, the 2021/2022 Biotech Bear market knocked out nearly all biotech innovators. Nevertheless, certain rare companies like Regenxbio are defying bear market expectations. Asides from the recent AbbVie mega partnership, Regenxbio's RGX314 is ...

Summary Third Harmonic Bio has filed proposed terms for a $153 million IPO. The firm is developing treatments for hives, asthma and gastrointestinal conditions. THRD is a promising biotech, but interested investors would likely need to wait until 2024 or 2025 to see a potentia...

Summary Viatris's total revenue was $4,116.8 million in Q2 2022, down 10.1% year-on-year. Sales of the company's branded medicines have been declining since the formation of Viatris in 2020. The company has a dividend yield of 5.08%, but dividend payouts are at risk from 2026....

Summary IGRO's performance has been primarily driven by bad performance in European markets. Substantial financial exposure is favorable in a rate hike environment. Moreover, aristocratic, blue chip yield exposures should be appreciated by income investors. Its portfolio i...

Summary EFV represents a traditional profile of value stocks. It offers high earnings yield and dividend yields, with substantial US financial exposures. The heavy financial exposures work out for the current environment, EFV looks like a decent ETF. The iShares MSCI EAF...

Novartis is a global healthcare company with a research-driven focus on pharmaceuticals, both prescription-based and generic. Valued at a one-year forward P/E of < x14, Novartis trades at a discount to fair value, in my opinion. Novartis relative valuation implies a material di...

PBCAR0191 is being explored in a phase 1/2 study in patients with relapsed/refractory Non-Hodgkin Lymphoma and r/r B-cell Acute Lymphoblastic Leukemia. Data updates from PBCAR0191, PBCAR19B for non-Hodgkin's Lymphoma and PBCAR269A for multiple myeloma are expected before end of 2...

Kahn Brothers' 13F portfolio value decreased from ~$788M to ~$743M this quarter. New York Community Bancorp, Citigroup, VOXX International, and ViewRay were increased while decreasing Patterson-UTI Energy during the quarter. The portfolio continues to be very concentrated with the...